Krina Patel, MD | Authors

Triplet and Quadruplet Induction Regimens for Transplant-Eligible NDMM: Focus on GRIFFIN and MASTER Trials

March 25, 2022

An overview of the triplet and quadruplet induction treatment regimens available for patients with transplant-eligible multiple myeloma and key clinical trials studying daratumumab and isatuximab presented at ASH 2021, with emphasis on the GRIFFIN, MASTER and GMMG-HD7 studies.